Sac-TMT and Bevacizumab for Triple-Negative Breast Cancer Brain Tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of two drugs (Sac-TMT and bevacizumab) to treat triple-negative breast cancer that has spread to the brain. Triple-negative means the cancer cells lack three common markers, making it harder to treat with standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Triple-negative breast cancer (hormone receptor negative and HER2 negative) with confirmed brain metastases (tumors in the brain) visible on MRI, at least 1 cm in size
- Good overall health status (ECOG score 0–2, meaning you can perform daily activities with minimal limitation)
- Normal or near-normal blood counts, liver function, kidney function, and heart function
- No prior treatment with bevacizumab (a blood vessel-blocking drug) or certain chemotherapy drugs, except in specific situations
- Life expectancy of at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (SHR-A1921 and Avastin) to see if it can shrink or slow brain tumors caused by triple-negative breast cancer. It’s for people whose breast cancer has spread to the brain and haven’t had radiation to the brain yet.
This trial is testing a combination of a targeted drug (Sacituzumab Govitecan) and radiation to the head for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this combination can help shrink brain tumors and improve outcomes.
This study tests a combination of two drugs—Sacituzumab Tirumotecan (Sac-TMT) and an immunotherapy called KL-A167—given before surgery to shrink triple-negative breast tumors. It aims to improve outcomes for people with early-stage, high-risk breast cancer who have not yet had any treatment.
This study tests a combination of radiation therapy, chemotherapy drugs (platinum-based), and two immunotherapy medications (adebrelimab and bevacizumab) for triple-negative breast cancer that has spread to the brain. The goal is to shrink tumors and improve survival when surgery or standard radiation alone isn't an option.
This Phase 2 study tests a treatment for people with triple-negative breast cancer that has spread to the brain. It’s designed for situations where the cancer can’t be safely cured with surgery or focused radiation.
This trial tests a new drug called sacituzumab tirumotecan (Sac-TMT) for people with triple-negative breast cancer that has spread to the brain. It aims to see if the drug can shrink or control brain tumors without needing immediate radiation or surgery.
Hear when a new Brain Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.